Discussion
In this study, we performed a comprehensive analysis of the disease burden in SMA by evaluating direct and indirect cost as well as the disease-specific HRQOL. Our results revealed a mean direct COI of €54,721/y per patient which was about 14 times higher than the average health expenditure per patient in Germany in 2013 [
19].
The highest overall demand for medical and care services was identified in SMA I, resulting in significantly higher cost compared to that of SMA II and III. Nevertheless, SMA I patients utilized respiratory devices and sleep laboratory tests to a lower extent than SMA II patients. Although respiratory failure is the most frequent cause of death in these young children [
4], we found that not all of them were ventilated, which is in line with the patient characteristics within the German SMA registry (Table
1). The low ventilation rates in SMA I patients in Germany could be attributed to differences regarding the availability of expert SMA treatment centers, or different preferences of physicians and parents towards ventilation [
12]. The use of medical aids seemed to be of secondary importance in SMA I, maybe due to the reduced physical development of SMA I patients. More importantly, this result might even suggest a possible shortage of medical aids (e.g. care aids or adapted beds) for this age group. The results of our study contribute to the transparency of the current consumption of resources of SMA patients in Germany. The use of psychological assistance turned out to be low in general, although previous publications showed a need not only for patients but also for the parents faced with a devastating disease affecting their kids [
20]. Moreover, access to inpatient and outpatient rehabilitation programs seemed to be low, possibly revealing a supply gap in specialized rehabilitation centers.
As far as we know, this is the first study conducting a detailed health services evaluation to investigate the economic burden of SMA in Germany. Larkindale et al. analyzed the COI of different neuromuscular diseases (SMA, ALS, DMD, DM) in the US in 2010. However, COI results for SMA were not mentioned in the publication due to the small sample size and difficulties in an adequate classification of SMA subtypes [
21]. This emphasizes the need for a detailed analysis of a genetically defined and comprehensively diagnosed group of SMA patients and highlights the importance of our study. Nevertheless, the results for SMA were published online by the US muscular dystrophy association (MDA). In contrast to our findings, higher costs were found in the patient group with diagnosis before/at age 3 ($184,647 per patient), but lower costs for patients with later onset ($45,750 per patient) [
22]. These discrepancies may result from (1) differences in the origin of data (commercial, Medicare, patient-reported), (2) the definition of different subgroups (age at diagnosis vs. defined SMA subtypes), (3) the methodological differences in valuing COR, (4) general disparities between the US and German health care systems, e.g. incentives for both health care providers and patients or compensation systems, (5) differences in standards of care as recently analyzed by Bladen et al. [
12] and (6) the varying characteristics of the populations with regard to morbidity and demography. These factors may influence country-specific COR and resulting cost and therefore limit the transferability and comparability of results between different countries [
23]. That is precisely why our findings cannot easily be translated to other countries or other diseases. Nevertheless, the MDA study roughly confirms our results of higher cost in SMA I/SMA with early onset, which result from the higher level of COR and the care needed by these severely affected patients [
22]. We previously reported similar results for dystrophinopathies in Germany and showed that health care expenditures increased with the progression of the disease and the increasing loss of an individual’s self-dependency [
6].
According to our results, SMA type I patients caused the highest informal care cost, reflecting both the severity of the disease and greater need for care. SMA I patients typically have a drastically shortened life expectancy of <2 years [
24,
25]. Even healthy babies and young children are demanding with regard to the attention and care that needs to be provided by the parents. Although we have assessed the informal care along with its cost in SMA, the comparability regarding the effort which is usually devoted to healthy children remains limited because of lack of publications in this field. Recently, COI analyses assessed informal care as a main cost driver in neuromuscular diseases, showing an increasing loss of family income together with increasing care need and dependency [
6,
21,
26]. These findings fully apply to SMA. We found that a high proportion of working parents (esp. of SMA I patients) had to reduce or even quit their jobs to be able to care for their affected child, leading to a reduced family income. We estimated the average annual informal care cost per patient at €20,170. Since we excluded working parents from our care cost estimation to prevent double counting of indirect cost and informal care cost, our results may even underestimate real care expenditures (for example, the average annual informal care cost per patient including working and non-working parents is much higher at €34,871). Besides care cost, indirect cost was previously described as a major cost driver in dystrophinopathies [
6,
26] and our results show similar findings in SMA. We estimated that indirect cost was most prominent in SMA II and III due to the loss of productivity of patients and/or their parents. Moreover, partners took over a major part of care in the group of adult patients, mainly in SMA III. Since we only analyzed the employment status of the patient itself or of one parent, indirect cost may be much higher when taking the second parent and/or other family members into account.
Altogether, we estimated a total economic burden of €106.5 million per year in Germany using prevalence data from Northern England [
18]. Obviously, more precise assessments of country-specific epidemiologic data are urgently needed. One major step might be the implementation of patient registries in rare diseases like SMA. For this study, we utilized the German SMA patient registry (
www.sma-register.de) [
12] resulting in a response rate of >70 %, which is a very good result for a cross-sectional study dealing with sensitive areas of life such as cost, handicaps and individual problems.
Patient-reported outcomes (PRO) as HRQOL help to understand the perceived health state from a patient perspective, e.g. the individual impairment resulting from symptoms and disabilities, and reveals impacts on other dimensions of independent living [
27]. Particularly in chronic diseases, HRQOL results can illustrate needs and shortcomings in health care, hopefully leading to improvements in services for adult [
28] and pediatric/adolescent patients [
29,
30]. In our study, HRQOL increased from SMA I to the milder SMA III phenotype, which is consistent with the results of a previous study in SMA II and III, in which a higher HRQOL in SMA III compared to SMA II had been shown [
31]. Interestingly, in a Brazilian study, the self-reported HRQOL of children with SMA II/III (aged >4y) was irrespective of motor ability and SMA subtype (SMA II: 55.85 vs. SMA III: 52.94) [
32]. However, they utilized the Autoquestionnaire Qualité de Vie Enfant Imagé (AUQEI) to assess HRQOL, a generic tool covering function, family, leisure, autonomy and other parameters, while we used the disease-specific instrument PedsQL™
©to better determine differences between the SMA subtypes. Additionally, the assessment of different disease-related dimensions allows for a more precise comprehension of the important problems of patients in their daily lives. Thus, SMA had the most important impact on the dimensions ‘problems with the neuromuscular disease’, which encompasses disease-associated handicaps, and, secondly, ‘family resources’, which is related to familial financial and social aspects. The results of our study are confirmed by the results of a recent investigation in the Czech Republic in which the disease-specific HRQOL in SMA patients aged 3–18 years was similarly analyzed with the PedsQL™
© 3.0 Neuromuscular Module [
33].
A potential limitation of our study might be a bias due to the utilization of a SMA patient registry to recruit study participants. Patients and families join the registry voluntarily; therefore, highly compliant and dedicated participants may be overrepresented. Furthermore, although SMA I is the most common SMA subtype, the life expectancy of patients is very limited. Given the low prevalence and small number of cases in this subgroup, our cost data for SMA I must be seen against this background. Additionally, in a retrospective study, recall bias may be a systematic error when estimating COI based on patient reported data from the past. Moreover, we used minimum prices to estimate the economic burden, possibly leading to the underestimation of the exact COI, and as mentioned above, the indirect cost may be much higher particularly when taking the impact on more than one family member into account.
In summary, our study provides the first comprehensive economic analysis of SMA in Germany from the perspective of patients, their families and society. Different innovative therapies are currently being investigated ‘from bench to bedside’, e.g. gene therapy, molecular therapy with antisense oligonucleotides, and small molecules, which hopefully will soon be available to treat this devastating disease [
34,
35]. In this context, our study results show that new innovative therapies modifying the severity of SMA into a milder phenotype have the potential to reduce COR together with COI. However, innovative therapies may go hand in hand with high cost due to research and particularly clinical development activities. Considering this, a precise estimation of overall cost is not feasible. Modifying the severity of SMA towards a milder phenotype may be connected with improvements in patients’ quality of life. Although COI in SMA II was seen to be almost as high as in SMA I, SMA II patients showed a significantly higher quality of life. This further underlines the huge need for early-stage treatment and adequate support to reduce COR and to improve HRQOL.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KHN and MCW designed the study with input from all authors. CK and JZ designed the study questionnaire with input from the other authors. OS-K and MCW coordinated ethics application. CK, OS-K and ST managed the acquisition of data. CK, OS-K, ST and ES analyzed data and interpreted findings with input from the other authors. CK and ES conducted statistical analyses with input from KHN and MCW. CK and OS-K drafted the manuscript. All authors reviewed the final manuscript and approved the decision to submit for publication. CK and OS-K as first authors and MCW and KHN as last authors equally contributed to this manuscript.
CK, MSc, is a research assistant and doctoral student with special interest in pharmacoeconomic analysis at the Institute for Healthcare Management and Health Sciences, University of Bayreuth.
OS-K, MD, is resident physician with special interest in neuromuscular disorders and health care evaluations in rare disorders at the Hannover Medical School, Dept. of Neurology, Hannover, Germany. Before, she worked at the Friedrich-Baur-Institute, Department of Neurology of the Ludwig-Maximilians-University in Munich and conducted numerous projects within this working group.
ST is a licensed physiotherapist and registry curator of the German DMD/BMD patient registry located at the Friedrich-Baur-Institute, Department of Neurology of the Ludwig-Maximilians-University in Munich.
ES, MSc, is a research assistant and doctoral student with special interest in pharmacoeconomic analysis at the Institute for Healthcare Management and Health Sciences, University of Bayreuth.
JZ, MSc, PhD, is a health economist and postdoctoral fellow. In addition, JZ is a licensed physiotherapist.
PR, MD, MA, is senior physician and assistant professor of neurology with special interest in neuromuscular disorders and palliative care at the Friedrich-Baur-Institute, Department of Neurology of the Ludwig-Maximilians-University in Munich.
MCW, MD, MA, is senior physician and associate professor of neurology with special interest in neuromuscular disorders and leading position at the Friedrich-Baur-Institute, Department of Neurology of the Ludwig-Maximilians-University in Munich.
KHN, DSc, PhD, is an associate professor of health economics with a further specialization in innovation management and pharmacoeconomics as well as current head of the Institute for Healthcare Management and Health Sciences, University of Bayreuth.